Experimental drug may help people with bipolar disorder

LONDON Tue Jan 8, 2013 9:38pm IST

A woman holds a medicine in Leicester, central England February 26, 2008 in this posed photograph. REUTERS/Darren Staples/Files

A woman holds a medicine in Leicester, central England February 26, 2008 in this posed photograph.

Credit: Reuters/Darren Staples/Files

Related Topics

Stocks

   

LONDON (Reuters) - A drug for bipolar disorder that works like lithium - the most common and effective treatment - but without lithium's side-effects has been identified by British researchers in tests on mice.

Scientists say the drug, ebselen, may be a swift answer to long-sought after better medications for patients with the manic depressive disorder, since it is already known to be safe.

If the drug could be "repurposed" and licensed for the treatment of bipolar disorder, it could reduce the unpleasant side effects of weight gain, thirst and potential kidney damage that patients risk when taking lithium.

"Ebselen is an experimental drug that has been tested in people for other conditions, and does not have problematic side effects like lithium does," said Grant Churchill of the department of pharmacology at Britain's Oxford University.

Bipolar disorder effects around 1 percent of the population worldwide and sufferers can experience moods that swing from one extreme to another, and have periods of depression and mania lasting several weeks or longer. These high and low phases are often so extreme they interfere with everyday life and work.

In a telephone interview Churchill said that in tests, his team found that mice who were made manic with small doses of amphetamines were able to be calmed again with ebselen.

"In mice, ebselen works like lithium," Churchill said. "Now we urgently need to see if it works like lithium in people."

Some 60 years after it was first discovered, lithium - a mood stabiliser that can protect against both depression and mania, and reduce the risk of suicide - remains the most effective long-term treatment.

But it is very toxic - at only twice the right dose it could kill a patient, Churchill said - and its adverse side-effects mean many people stop taking the drug and relapse into episodes of mania and depression.

Churchill worked with Sridhar Vasudevan to filter through a library of existing drugs - the U.S. National Institutes of Health Clinical Collection - that are considered safe but do not currently have a proven use.

They screened the library for any drugs that blocked an enzyme that is key to lithium's success and found ebselen was a possible lithium mimic.

"This is one of the first handful of examples of drug repurposing, where a new use has been found for an existing drug," Vasudevan said.

Ebselen is an antioxidant originally developed up to late stage, or phase III, clinical trials by the Japanese firm Daiichi Sankyo (4568.T) for the treatment of stroke, but which never reached market and is now out of patent.

Vasudevan said his study, reported in the journal Nature Communications, showed ebselen had the same or similar action as lithium in the brains of mice, blocking the same enzyme.

The researchers are a now starting a small study in healthy human volunteers to look for effects on brain function. If that shows ebselen has similar effects to lithium, they plan to move to second stage trial in bipolar patients. (Editing by Pravin Char)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

China Praised

China Praised

United States praises China's growing role in Afghanistan.  Full Article 

New MERS Cases

New MERS Cases

Saudi Arabia finds six new MERS cases as outbreak grows.  Full Article 

Hazing Death Case

Hazing Death Case

South Korean court-martial jails soldiers in hazing death case.  Full Article 

Fighting Ebola

Fighting Ebola

Why do some survive Ebola? Sierra Leone study offers clues.  Full Article | Related Story 

Famine Conditions

Famine Conditions

At least 3 million in Somalia in need of aid - U.N. Secretary General.  Full Article 

Islamic State Seige

Islamic State Seige

Kurdish convoy heads to Syria to take on Islamic State.  Full Article 

Tunisia Election

Tunisia Election

Tunisia's main secular party wins most seats - authorities.  Full Article 

Failed Launch

Failed Launch

Probe of Virginia rocket blast begins; space station supplied.  Full Article 

Active Volcano

Active Volcano

Hawaii lava crosses residential property, threatens more homes.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage